Page last updated: 2024-11-06

prednisolone and Neoplasm Metastasis

prednisolone has been researched along with Neoplasm Metastasis in 111 studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research Excerpts

ExcerptRelevanceReference
"The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo."9.30Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE, 2019)
"To determine the effect of prednisolone on severe hypercalcaemia in women with metastatic breast cancer, 30 patients with serum ionized calcium above 1."9.07Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study. ( Ejlertsen, B; Holmegaard, SN; Krarup-Hansen, A; Kristensen, B; Mouridsen, H; Transbøl, I, 1992)
"Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)."9.05The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985)
"Fifty patients with metastatic breast cancer were treated with a combination of vincristine, Adriamycin and prednisolone (VAP) at four weekly intervals."7.66Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone. ( Baker, JW; Dady, PJ; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Powles, TJ; Russell, JA, 1978)
"Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent."5.39Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. ( Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S, 2013)
"Radiation-induced gastritis is an infrequent cause of gastrointestinal bleeding."5.38Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report. ( Chen, Y; Ren, ZG; Wang, Y; Wang, YH; Xie, XY; Zhang, L, 2012)
"The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo."5.30Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE, 2019)
"To determine the effect of prednisolone on severe hypercalcaemia in women with metastatic breast cancer, 30 patients with serum ionized calcium above 1."5.07Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study. ( Ejlertsen, B; Holmegaard, SN; Krarup-Hansen, A; Kristensen, B; Mouridsen, H; Transbøl, I, 1992)
"Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)."5.05The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985)
"Ninety-one assessable elderly women (greater than 65 years) with advanced breast cancer were treated with prednisolone 15 mg (or cortisone 75 mg) daily after primary endocrine treatment (estrogens, androgens or tamoxifen)."3.66Corticosteroids for elderly patients with breast cancer. ( Hayward, JL; Knight, RK; Minton, MJ; Rubens, RD, 1981)
"Fifty patients with metastatic breast cancer were treated with a combination of vincristine, Adriamycin and prednisolone (VAP) at four weekly intervals."3.66Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone. ( Baker, JW; Dady, PJ; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Powles, TJ; Russell, JA, 1978)
" Most common adverse event was nasopharyngitis (15/50 patients, 30."3.01Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. ( Arai, G; Furukawa, J; Iinuma, M; Kamiya, N; Kikukawa, H; Kobayashi, H; Kobayashi, K; Maniwa, A; Mikami, K; Nakashima, T; Nakatsu, H; Nasu, Y; Okuno, N; Satoh, T; Tanabe, K; Uemura, H, 2021)
" Ipatasertib bioavailability and M1 formation increased after multiple dosing, resulting in an increase in exposure beyond that expected from accumulation alone."3.01Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. ( Chanu, P; Kotani, N; Sane, R; Wade, JR; Wang, N; Wilkins, J; Winkler, J; Yoshida, K, 2021)
" Adverse events (AEs) possibly related to cabazitaxel occurred in 143 (93."2.79Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. ( Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A, 2014)
"Abiraterone acetate has been approved in >70 countries for chemotherapy-naïve metastatic castration-resistant prostate cancer patients."2.79A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). ( Akaza, H; Hashine, K; Imanaka, K; Matsubara, N; Nishiyama, T; Ozono, S; Satoh, T; Suzuki, H; Uemura, H, 2014)
"Seventy patients with breast cancer (stage IIIb--IV) were randomized by an "envelope" method into 2 groups, each including 35 persons."2.64[Combined drug treatment of far-advanced forms of breast cancer]. ( Borisov, AI, 1978)
"Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC."2.47Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. ( Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R, 2011)
"Advanced prostate cancer is typically sensitive to androgen-deprivation therapy, but invariably progresses to the castration-resistant state."2.47Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. ( de Bono, JS; Massard, C; Michels, RM; Sartor, O, 2011)
"Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases."2.43The changing pattern of management for hormone-refractory, metastatic prostate cancer. ( Bloomfield, D; James, ND; Luscombe, C, 2006)
"Liver metastasis emerged two months after surgical resection, and the histology of the proliferating spindle cells sampled by a fine-needle biopsy was similar to that of the rectal tissue."1.56Aggressive Inflammatory Myofibroblastic Tumor without Anaplastic Lymphoma Kinase Gene Rearrangement in the Rectum with Liver Metastasis. ( Fukuda, S; Hiroshima, Y; Iijima, K; Koizumi, S; Matsuhashi, T; Nanjo, H; Ohba, R; Shimodaira, Y; Sugawara, K; Suzuki, Y; Watanabe, N, 2020)
"Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel."1.40Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. ( Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014)
"Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent."1.39Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. ( Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S, 2013)
"Radiation-induced gastritis is an infrequent cause of gastrointestinal bleeding."1.38Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report. ( Chen, Y; Ren, ZG; Wang, Y; Wang, YH; Xie, XY; Zhang, L, 2012)
" Treatment continued without obvious side effects, and PDL dosage was tapered to 10 mg/day."1.36[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects]. ( Kishimoto, H; Nakamura, M; Otagiri, N; Sasahara, K; Tauchi, K; Tsukada, Y; Yoshifuku, S, 2010)
" Both therapeutic agents were suspected as a possible cause of this adverse event."1.34Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. ( Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C, 2007)
" The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide."1.32Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004)
"A case of osteogenic sarcoma of the maxilla is described."1.26Chemotherapy in the treatment of osteogenic sarcoma of the maxilla (case report). ( Nakajima, T; Yokobayashi, T, 1978)
"The apparent risk of early CNS disease suggests that prophylactic CNS therapy should be given early in the treatment of acute non-myelogenous leukaemia."1.26Early central nervous system involvement in adults with acute non-myelogenous leukaemia. ( Beard, ME; Brearley, RL; Brown, L; Crowther, D; Lister, TA; Paxton, A; Whitehouse, JM; Wrigley, PF, 1977)
"At autopsy a large single metastasis was found in the right atrium and tumour emboli in the pulmonary artery."1.26Rapid platelet consumption in a case of metastatic osteogenic sarcoma of the breast. ( Johansson, S; Kutti, J; Olsson, LB, 1978)
"Estramustine has been shown previously to be an effective drug in the treatment of metastatic prostatic cancer, demonstrating significant objective and subjective responses in long-term non-randomized trials and in other randomized trials."1.26The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. ( Chu, TM; Gaeta, JF; Gibbons, RP; Johnson, DE; Loening, SA; Murphy, GP; Prout, GR; Saroff, J; Schmidt, JD; Scott, WW; Slack, N; Soloway, MS; Wajsman, Z, 1979)

Research

Studies (111)

TimeframeStudies, this research(%)All Research%
pre-199068 (61.26)18.7374
1990's4 (3.60)18.2507
2000's9 (8.11)29.6817
2010's25 (22.52)24.3611
2020's5 (4.50)2.80

Authors

AuthorsStudies
George, DJ1
Shimodaira, Y1
Sugawara, K1
Fukuda, S1
Suzuki, Y1
Watanabe, N1
Koizumi, S1
Ohba, R1
Hiroshima, Y1
Matsuhashi, T1
Nanjo, H1
Iijima, K1
Yoshizawa, T1
Yamaguchi, K1
Kawata, N1
Ryuzaki, H1
Ogawa, M1
Obinata, D1
Mochida, J1
Takahashi, S1
Kobayashi, K1
Okuno, N1
Arai, G1
Nakatsu, H1
Maniwa, A1
Kamiya, N1
Satoh, T3
Kikukawa, H1
Nasu, Y1
Uemura, H4
Nakashima, T1
Mikami, K1
Iinuma, M1
Tanabe, K2
Furukawa, J1
Kobayashi, H1
Crabb, SJ1
Griffiths, G1
Marwood, E1
Dunkley, D1
Downs, N1
Martin, K1
Light, M1
Northey, J1
Wilding, S1
Whitehead, A1
Shaw, E1
Birtle, AJ2
Bahl, A1
Elliott, T1
Westbury, C1
Sundar, S1
Robinson, A2
Jagdev, S1
Kumar, S1
Rooney, C1
Salinas-Souza, C1
Stephens, C1
Khoo, V1
Jones, RJ3
Yoshida, K1
Wilkins, J1
Winkler, J1
Wade, JR1
Kotani, N1
Wang, N1
Sane, R1
Chanu, P1
Fizazi, K1
Tran, N1
Fein, L1
Matsubara, N3
Rodriguez-Antolin, A1
Alekseev, BY1
Özgüroğlu, M1
Ye, D1
Feyerabend, S1
Protheroe, A2
De Porre, P1
Kheoh, T1
Park, YC1
Todd, MB1
Chi, KN1
James, ND2
de Bono, JS2
Spears, MR1
Clarke, NW1
Mason, MD1
Dearnaley, DP1
Ritchie, AWS1
Amos, CL1
Gilson, C1
Matheson, D1
Millman, R1
Attard, G1
Chowdhury, S1
Cross, WR1
Gillessen, S1
Parker, CC1
Russell, JM2
Berthold, DR1
Brawley, C1
Adab, F1
Aung, S1
Bowen, J1
Brock, S1
Chakraborti, P1
Ferguson, C1
Gale, J1
Gray, E1
Hingorani, M1
Hoskin, PJ1
Lester, JF1
Malik, ZI1
McKinna, F1
McPhail, N1
Money-Kyrle, J1
O'Sullivan, J1
Parikh, O1
Srihari, NN1
Thomas, C1
Wagstaff, J2
Wylie, J1
Zarkar, A1
Parmar, MKB1
Sydes, MR1
Struss, WJ1
Black, PC1
Rulach, RJ1
McKay, S1
Neilson, S1
White, L1
Wallace, J1
Carruthers, R1
Lamb, C1
Cascales, A1
Marashi, H1
Glen, H1
Venugopal, B1
Sadoyze, A1
Sidek, N1
Alhasso, A2
Dodds, D1
Laskey, J1
MacLeod, N1
Biró, K1
Budai, B1
Szőnyi, M1
Küronya, Z1
Gyergyay, F1
Nagyiványi, K1
Géczi, L1
Nühnen, VP1
Schön, MP1
Mössner, R1
Adler, NR1
Murray, WK1
Brady, B1
McCormack, C1
Pan, Y1
Smith, M1
Parker, C1
Saad, F1
Miller, K1
Tombal, B1
Ng, QS1
Boegemann, M1
Matveev, V1
Piulats, JM1
Zucca, LE1
Karyakin, O1
Kimura, G1
Nahas, WC1
Nolè, F1
Rosenbaum, E1
Heidenreich, A2
Kakehi, Y2
Zhang, A1
Krissel, H1
Teufel, M1
Shen, J1
Wagner, V1
Higano, C1
Ikeda, M1
Fujita, T1
Amoh, Y1
Mii, S1
Matsumoto, K1
Iwamura, M1
Bracarda, S1
Mason, M1
Ozen, H1
Sengelov, L1
Van Oort, I1
Papandreou, C1
Fossa, S1
Hitier, S1
Climent, MA1
Castellano, D1
Antón Aparicio, LM1
Esteban, E1
Sánchez-Hernández, A1
Germà, JR1
Batista, N1
Maroto, P1
Pérez-Valderrama, B1
Luque, R1
Méndez-Vidal, MJ1
Lee, JL1
Park, SH1
Koh, SJ1
Lee, SH1
Kim, YJ1
Choi, YJ1
Lee, J1
Lim, HY1
Suzuki, H1
Nishiyama, T2
Hashine, K2
Imanaka, K2
Ozono, S3
Akaza, H3
Terai, A1
Yokomizo, A2
Nakatani, T1
Moriceau, G1
Guillot, A1
Pacaut, C1
Méry, B1
Falk, AT1
Trone, JC1
Collard, O1
De Laroche, G1
Fournel, P1
Merrouche, Y1
Magné, N1
Shiota, M1
Takeuchi, A1
Kiyoshima, K1
Inokuchi, J1
Tatsugami, K1
Shiga, KI1
Koga, H1
Yamaguchi, A1
Naito, S1
Eto, M1
Okamoto, K1
Ichinose, M1
Rassy, EE1
Assi, T1
Rizkallah, J1
Kattan, J1
Rice, CM1
Beric, V1
Love, S1
Scolding, NJ1
Tsukada, Y1
Tauchi, K1
Nakamura, M1
Kishimoto, H1
Yoshifuku, S1
Otagiri, N1
Sasahara, K1
Ansari, J1
Hussain, SA1
Mahmood, R1
Ansari, A1
Glaholm, J1
Sartor, O1
Michels, RM1
Massard, C1
Nishimura, K1
Nonomura, N1
Kanayama, HO1
Miura, T1
Miki, T1
Arai, Y1
Ogawa, O1
Fujita, R1
Nonomura, K1
Mizokami, A1
Hoshi, S1
Zhang, L1
Xie, XY1
Wang, Y1
Wang, YH1
Chen, Y1
Ren, ZG1
Başpinar, O1
Uçar, C1
Baysal, T1
Oran, B1
Karaaslan, S1
ROBSON, NL1
SCHMIDT, E1
SCHMIDT, FW1
OYAMA, T1
IRVINE, WT1
FRECKMAN, HA2
FRY, HL1
MENDEZ, FL1
MAURER, ER1
JAMIESON, WJ1
RUDERMAN, NB1
HALL, TC1
MANNHEIMER, IH1
Kopp, HG1
Kanz, L1
Hartmann, JT1
Miyoshi, I1
Saito, T1
Bandobashi, K1
Ohtsuki, Y1
Taguchi, H1
Bloomfield, D1
Luscombe, C1
Collins, R1
Trowman, R1
Norman, G1
Light, K1
Birtle, A1
Fenwick, E1
Palmer, S1
Riemsma, R1
Boeck, S1
Hausmann, A1
Reibke, R1
Schulz, C1
Heinemann, V1
Valencia-Parparcén, J1
Candia-Candia, E1
Kaltofen, G1
Bramwell, VH1
Howell, A1
Scarffe, H1
Crowther, D3
Sellwood, RA1
Andersson, L1
Edsmyr, F1
Esposti, PL1
Hedlund, PO1
Rönström, L1
Beckley, S1
Wajsman, LZ1
Slack, NH1
Murphy, GP2
Thatcher, N1
Wilkinson, P1
Palmer, M1
Dymarskiĭ, LIu1
Aleksandrova, GI1
Sanchakova, AV1
Minton, MJ1
Knight, RK1
Rubens, RD2
Hayward, JL1
Wilmanns, W2
Hartenstein, R1
Sauer, H1
Binsack, T1
Datta, SN1
Thomas, K1
Matthews, PN1
Gerritsen, RJ1
Teske, E1
Kraus, JS1
Rutteman, GR1
Culine, S1
Droz, JP1
Wahid, FS1
Fun, LC1
Keng, CS1
Ismail, F1
Laver, JH1
Mahmoud, H1
Pick, TE1
Hutchinson, RE1
Weinstein, HJ1
Schwenn, M1
Weitzman, S1
Murphy, SB1
Ochoa, S1
Shuster, JJ1
Yokobayashi, T1
Nakajima, T1
Sutcliffe, SB1
Wrigley, PF2
Stansfeld, AG1
Malpas, JS1
Umsawasdi, T2
Chainuvati, T1
Hitanant, S1
Nilprabhassorn, P2
Viranuvatti, V1
Lister, TA1
Whitehouse, JM1
Beard, ME1
Paxton, A1
Brearley, RL1
Brown, L1
Johansson, S1
Kutti, J1
Olsson, LB1
Borisov, AI1
Gibbons, RP1
Johnson, DE1
Prout, GR1
Schmidt, JD1
Soloway, MS1
Loening, SA1
Chu, TM1
Gaeta, JF1
Saroff, J1
Wajsman, Z1
Slack, N1
Scott, WW1
Russell, JA2
Baker, JW2
Dady, PJ3
Ford, HT3
Gazet, JC3
McKinna, JC1
Nash, AG2
Powles, TJ4
McKinna, JA1
Wood, RA1
Cziráki, L2
OO, M2
Kaye, SB1
Ikram, H1
Hoshino, T1
Wilson, CB1
Leese, CL1
Bondy, PK1
Trapeznikov, NN1
Kupin, VI1
Radzikhovskaia, RM1
Kadagidze, ZG1
Qasim, MM1
Zhukovskaia, ES1
Gorbunova, VA1
Khvatova, NV1
Gilbert, HA1
Yettra, M1
Gordon, J1
Kagan, AR1
Hirano, M1
Okamoto, M1
Maruyama, F1
Ezaki, K1
Shimizu, K1
Ino, T1
Matsui, T1
Sobue, R1
Shinkai, K1
Miyazaki, H1
Kristensen, B1
Ejlertsen, B1
Holmegaard, SN1
Krarup-Hansen, A1
Transbøl, I1
Mouridsen, H1
Bennett, A1
Melhuish, PB1
Patel, S1
Randles, H1
Stamford, IF1
Kojima, T1
Hoshino, A1
Ohara, K1
Kamiya, O1
Nagata, K1
Ito, Y1
Kinoshita, T1
Sugiura, I1
Yamada, M1
Sato, H1
Mitchell, I1
Deshpande, N1
Millis, R1
Taylor, SG1
Keidan, SE1
Helson, L1
Wollner, N1
Murphy, ML1
Schwartz, MK1
Maas, B1
Ruhrmann, G1
Alferova, MS1
Izmailova, GE1
Sviatukhina, OV1
Starichkov, MS1
Magrath, IT1
Mugerwa, J1
Bailey, I1
Olweny, C1
Kiryabwire, Y1
Franke, HD1
Landbeck, G1
Timmermann, J1
Winkler, K1
Willoughby, ML1
Saikia, NK1
MacKie, RM1
McQueen, A1
Evans, DB1
Calne, RY1
Buckle, R1
Fairley, GH1
Freeman, JE1
Hermann, J1
Zintl, F1
Plenert, W1
Vishniakova, EG1
Gossart, R1
Kulakowski, S1
Achslogh, J1
Malherbe, A1
de Vaan, GA1
Marcar, JR1
Schretlen, ED1
Ishimori, S1
Spiers, AS1
Wendel, H1
Kochan, E1
Kröger, W1
Mitchell, AB1
Pinn, G1
Pegrum, GD1
Ryan, SJ1
Frank, RN1
Green, WR1
Szabolcsi, I1
Gáspár, P1
Komáromy, J1
Vogler, WR1
Furtado, VP1
Huguley, CM1
Bankl, H1
Geyer, G1
Jesserer, H1
Keibl, E1
Kucsko, L1
Kotzaurek, R1
Müller-Grotjan, H1
Liegl, O1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label Phase I/Randomised, Double Blind Phase II Study in Metastatic Castration Resistant Prostate Cancer of AZD5363 In Combination With Docetaxel and Prednisolone Chemotherapy (ProCAID)[NCT02121639]Phase 1/Phase 2160 participants (Actual)Interventional2014-01-29Completed
A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622]Phase 2100 participants (Anticipated)Interventional2020-10-07Recruiting
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)[NCT01715285]Phase 31,209 participants (Actual)Interventional2013-02-12Completed
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791]Phase 1/Phase 230 participants (Anticipated)Interventional2023-11-30Not yet recruiting
A Single-center, Phase II Neoadjuvant Study of Abiraterone Acetate in the Treatment of Intraductal Carcinoma of the Prostate[NCT04736108]Phase 250 participants (Anticipated)Interventional2021-05-31Not yet recruiting
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476]Phase 2/Phase 311,992 participants (Actual)Interventional2005-07-08Active, not recruiting
A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predom[NCT02043678]Phase 3806 participants (Actual)Interventional2014-03-30Active, not recruiting
Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel [NCT01254279]Phase 3984 participants (Actual)Interventional2010-12-31Completed
A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration Resistant Prostate Cancer Patients Who Are Chemotherapy-Naïve[NCT01756638]Phase 248 participants (Actual)Interventional2012-06-06Completed
A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy[NCT01795703]Phase 247 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival (OS)

Overall survival was defined as the time from randomization to date of death from any cause. (NCT01715285)
Timeframe: Up to 66 months

Interventionmonths (Median)
Abiraterone Acetate+Prednisone+ADT53.32
Placebo + ADT36.53

Radiographic Progression-Free Survival (PFS)

Radiographic PFS was defined as the time (in months) interval from randomization to the first date of radiographic progression or death. Radiographic progression included progression by bone scan (according to modified Prostate Cancer Working Group 2 [PCWG2] criteria), defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria). As per the RECIST 1.1 guideline, progression requires a 20 percent (%) increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 millimeter (mm) in the sum as compared to nadir sum of diameter. (NCT01715285)
Timeframe: Up to 44 months

InterventionMonths (Median)
Abiraterone Acetate+Prednisone+ADT33.02
Placebo + ADT14.78

Time to Initiation of Chemotherapy

Time to initiation of chemotherapy was defined as the time (in months) interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months

Interventionmonths (Median)
Abiraterone Acetate+Prednisone+ADTNA
Placebo + ADT57.59

Time to Pain Progression

"Time to pain progression was defined as the time (in months) interval from randomization to the first date a participant experienced a greater than or equal to (>=) 30 percent (%) increase in Brief Pain Inventory-Short Form (BPI-SF) from baseline in the BPI-SF worst pain intensity (Item 3) observed at 2 consecutive evaluations (>=4) weeks apart. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 10 with 0 representing no pain and 10 representing pain as bad as you can imagine." (NCT01715285)
Timeframe: Up to 66 months

InterventionMonths (Median)
Abiraterone Acetate+Prednisone+ADT47.41
Placebo + ADT16.62

Time to Prostate-Specific Antigen (PSA) Progression

Time to PSA progression was defined as the time (in months) interval from the date of randomization to the date of PSA progression, according to PCWG2 criteria. PCWG2 defines PSA progression as the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL) or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later. (NCT01715285)
Timeframe: Up to 66 months

InterventionMonths (Median)
Abiraterone Acetate+Prednisone+ADT33.31
Placebo + ADT7.43

Time to Skeletal-Related Event

Time to skeletal-related event was defined as the earliest of the following: clinical or pathological fracture, spinal cord compression, palliative radiation to bone, or surgery to bone. (NCT01715285)
Timeframe: Up to 66 months

Interventionmonths (Median)
Abiraterone Acetate+Prednisone+ADTNA
Placebo + ADTNA

Time to Subsequent Therapy for Prostate Cancer

Time to subsequent therapy was defined as the time (in months) interval from the date of randomization to the date of initiation of subsequent therapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months

InterventionMonths (Median)
Abiraterone Acetate+Prednisone+ADT54.87
Placebo + ADT21.22

Number of Participants With Any Treatment-emergent Additional Primary Malignancies

Treatment-emergent additional primary malignancies were adverse events identified as additional primary malignancies that occurred after start of study treatment until the end of the treatment period. (NCT02043678)
Timeframe: From start of study treatment until 4 weeks after last study treatment, up to 65 months

InterventionParticipants (Count of Participants)
Radium-223 Dichloride + Abi/Pred26
Placebo + Abi/Pred25

Number of Participants With Treatment-emergent Bone Fractures

Treatment-emergent fractures were adverse events identified as fractures that occurred after start of study treatment until the end of the treatment period. All bone fractures and bone-associated events (e.g., osteoporosis) were reported as either AEs, or SAEs if the criteria of SAE were met, regardless of the investigator's causality assessment. (NCT02043678)
Timeframe: From start of study treatment until 4 weeks after last study treatment, up to 65 months

InterventionParticipants (Count of Participants)
Radium-223 Dichloride + Abi/Pred107
Placebo + Abi/Pred49

Overall Survival (OS)

OS was defined as the time (months) from the date of randomization to the date of death due to any cause. Subjects alive at the survival cut-off date were censored at the last date known to be alive. (NCT02043678)
Timeframe: From randomization until death from any cause, up to 67 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred30.1
Placebo + Abi/Pred34.8

Radiological Progression Free Survival (rPFS)

rPFS was defined as the time (months) from the date of randomization to the date of confirmed radiological progression or death (if death occurred before progression) based on independent assessment. (NCT02043678)
Timeframe: From randomization until the date of confirmed radiological progression or death, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred11.2
Placebo + Abi/Pred12.4

Symptomatic Skeletal Event Free Survival (SSE-FS)

SSE-FS was defined as time (months) from randomization to the earliest of onset date of skeletal symptoms treated with external beam radiotherapy (EBRT), onset date of pathological bone fracture, onset date of spinal cord compression, procedure date of tumor-related orthopedic surgery, or death from any cause. Subjects who died without prior SSE and ≥ 13 weeks after the last SSE assessment are censored at the last SSE assessment date. Subjects alive at the survival cut-off date are censored at the last date known to be alive. Subjects with multiple events are only counted for the category in which the first event occurred. If multiple SSE (component events) occur on the same date for 1 subject, the subject is only counted into 1 category in the order of: spinal cord compression > bone fracture > orthopedic surgery > EBRT. (NCT02043678)
Timeframe: From randomization until first onset of on-study symptomatic skeletal event (SSE) or death, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred22.3
Placebo + Abi/Pred26.0

Time to Cytotoxic Chemotherapy

Time to cytotoxic chemotherapy is time (months) from randomization to the earliest date of the first cytotoxic chemotherapy. Participants who have not started cytotoxic chemotherapy during the study were censored at the last assessment date. (NCT02043678)
Timeframe: From randomization until the date of first cytotoxic chemotherapy, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred29.5
Placebo + Abi/Pred28.5

Time to Opiate Use for Cancer Pain

Time to opiate use for cancer pain was defined as the interval from the date of randomization to the date of opiate use. (NCT02043678)
Timeframe: From randomization until the date of opiate use, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred19.0
Placebo + Abi/Pred22.6

Time to Pain Progression

Time to pain progression was defined as the interval from randomization to the first date a subject experienced pain progression, assessed by BPI-SF (see Baseline Characteristics) and defined as: an increase of 2 or more points in the average worst pain score (WPS) from baseline observed at 2 consecutive evaluations >= 4 weeks apart or initiation of short- or long-acting opioid use for pain for subjects with WPS 0 at baseline; an increase of 2 or more points in the average WPS from baseline observed at 2 consecutive evaluations ≥ 4 weeks apart and an average WPS of ≥ 4 OR initiation of short- or long-acting opioid use for pain for subjects with WPS 1 to 3 at baseline. Subjects without pain progression at the end of study are censored at the last date known to have not progressed: the last evaluation date for pain scores or last visit when recorded opiate use, whichever is last. Subjects with no on-study assessment or no baseline assessment are censored at the date of randomization. (NCT02043678)
Timeframe: From randomization until the date of pain progression based on pain score, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred14.4
Placebo + Abi/Pred18.7

Number of Participants With Any Study Drug-related Post-treatment Adverse Events Per Maximum Intensity

"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs that started after the treatment period were defined as post-treatment AEs. Drug-related AEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: After the treatment period, up to 46 months

,
InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4
Placebo + Abi/Pred3330
Radium-223 Dichloride + Abi/Pred3951

Number of Participants With Post-treatment Adverse Events

"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs that started after the treatment period were defined as post-treatment AEs. Drug-related AEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: After the treatment period, up to 46 months

,
InterventionParticipants (Count of Participants)
Any eventsAny drug-related eventsAny chemotherapy-related eventsAny additional primary malignancies
Placebo + Abi/Pred1339347
Radium-223 Dichloride + Abi/Pred13818316

Number of Participants With Post-treatment Bone Fractures

Post-treatment fractures were adverse events identified as fractures that occured after the end of the treatment period until participant died, was lost to follow-up, withdrew informed consent, actively objected to collection of further data, or was transitioned to the extended safety follow-up study. All bone fractures and bone-associated events (e.g., osteoporosis), were reported as either AEs, or SAEs if the criteria of SAE were met, regardless of the investigator's causality assessment. (NCT02043678)
Timeframe: After the treatment period, up to 46 months

,
InterventionParticipants (Count of Participants)
Lumbar vertebral fractureRib fractureSpinal compression fractureThoracic vertebral fractureTraumatic fractureOsteoporotic fracturePathological fracture
Placebo + Abi/Pred11112013
Radium-223 Dichloride + Abi/Pred00006612

Number of Participants With Post-treatment Chemotherapy-related Blood and Lymphatic System Disorders

Post-treatment blood and lymphatic system disorders were adverse events identified as blood and lymphatic system disorders that occurred after the end of the treatment period until participant died, was lost to follow-up, withdrew informed consent, actively objected to collection of further data, or was transitioned to the extended safety follow-up study. (NCT02043678)
Timeframe: After the treatment period, up to 46 months

,
InterventionParticipants (Count of Participants)
AnaemiaBone marrow failureFebrile neutropeniaLeukopeniaNeutropeniaPancytopeniaThrombocytopenia
Placebo + Abi/Pred4080312
Radium-223 Dichloride + Abi/Pred5151802

Number of Participants With Treatment-emergent Adverse Events

"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. AEs or SAEs occurring after start of study treatment until the end of the treatment period were defined as treatment-emergent AEs (TEAEs) or serious TEAEs. Drug-related TEAEs or serious TEAEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: From start of study treatment until the end of the treatment period, up to 65 months

,
InterventionParticipants (Count of Participants)
Any TEAEAny drug-related TEAERadium-223/Placebo-related TEAEAny serious TEAEAny drug-related serious TEAERadium-223/Placebo-related serious TEAE
Placebo + Abi/Pred38727192172297
Radium-223 Dichloride + Abi/Pred382265921753211

Number of Subjects With Radium-223/Placebo-related Treatment-emergent Adverse Events Per Maximum Intensity

"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. AEs or SAEs occurring after start of study treatment until the end of the treatment period were defined as treatment-emergent AEs (TEAEs) or serious TEAEs. Radium-223/placebo-related TEAEs or serious TEAEs were those with reasonable causal relationship to radium-223 or placebo decided by the investigators." (NCT02043678)
Timeframe: From start of study treatment until the end of the treatment period, up to 65 months

,
InterventionParticipants (Count of Participants)
TEAE - Grade 1TEAE - Grade 2TEAE - Grade 3TEAE - Grade 4Serious TEAE - Grade 2Serious TEAE - Grade 3Serious TEAE - Grade 4
Placebo + Abi/Pred5324132052
Radium-223 Dichloride + Abi/Pred4428191380

Reviews

10 reviews available for prednisolone and Neoplasm Metastasis

ArticleYear
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
    Anti-cancer agents in medicinal chemistry, 2011, Volume: 11, Issue:3

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cl

2011
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    The oncologist, 2011, Volume: 16, Issue:11

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ca

2011
SELECTION AND TREATMENT OF PATIENTS WITH ADVANCED BREAST CANCER.
    Clinical radiology, 1964, Volume: 15

    Topics: Adrenalectomy; Androgens; Breast; Breast Neoplasms; Cortisone; Estrogens; Female; Humans; Hypophysec

1964
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
    Prostate cancer and prostatic diseases, 2006, Volume: 9, Issue:3

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol

2006
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    British journal of cancer, 2006, Aug-21, Volume: 95, Issue:4

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Res

2006
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:12

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2000
Breast carcinoma presenting as immune thrombocytopenic purpura.
    International journal of hematology, 2001, Volume: 73, Issue:3

    Topics: Adult; Autoimmune Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Immunosuppr

2001
Review of basic concepts of cell kinetics as applied to brain tumors.
    Journal of neurosurgery, 1975, Volume: 42, Issue:2

    Topics: Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Astrocytoma; Brain; Brain Neoplasms; Cell

1975
Ectopic PTH syndrome, pseudohyperparathyroidism; hypercalcaemia of malignancy.
    Clinics in endocrinology and metabolism, 1974, Volume: 3, Issue:2

    Topics: Adenocarcinoma; Adenoma; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Carcinoma;

1974
[Diagnosis and therapy of acute lymphatic leukemia in childhood].
    Kinderarztliche Praxis, 1974, Volume: 42, Issue:12

    Topics: Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Lymp

1974

Trials

18 trials available for prednisolone and Neoplasm Metastasis

ArticleYear
Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Japanese journal of clinical oncology, 2021, Apr-01, Volume: 51, Issue:4

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protoc

2021
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 01-20, Volume: 39, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doceta

2021
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
    Journal of clinical pharmacology, 2021, Volume: 61, Issue:12

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Comb

2021
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    The New England journal of medicine, 2017, 07-27, Volume: 377, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C

2017
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:3

    Topics: Abiraterone Acetate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone N

2019
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm

2014
A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:12

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Prot

2014
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:12

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hum

2014
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
    International journal of clinical oncology, 2013, Volume: 18, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug-

2013
Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031).
    Urology, 1981, Volume: 17, Issue:5

    Topics: Aged; Antineoplastic Agents; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Huma

1981
Intermittent high-dose cyclophosphamide with and without prednisolone: a study of the relationships between toxicity, response and survival in metastatic lung cancer.
    Cancer, 1982, Sep-15, Volume: 50, Issue:6

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Therapy,

1982
Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
    The Journal of urology, 1997, Volume: 158, Issue:1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; M

1997
Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
    Leukemia & lymphoma, 2001, Volume: 42, Issue:3

    Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; D

2001
[Combined drug treatment of far-advanced forms of breast cancer].
    Voprosy onkologii, 1978, Volume: 24, Issue:12

    Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Dru

1978
Response of metastatic breast cancer to combination chemotherapy according to site.
    British medical journal, 1977, Nov-26, Volume: 2, Issue:6099

    Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu

1977
Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study.
    Journal of internal medicine, 1992, Volume: 232, Issue:3

    Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Calcium; Female; Fluid Therapy; Furosemide; Hum

1992
The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.
    Cancer chemotherapy and pharmacology, 1985, Volume: 15, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To

1985

Other Studies

83 other studies available for prednisolone and Neoplasm Metastasis

ArticleYear
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:7

    Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; B

2019
Aggressive Inflammatory Myofibroblastic Tumor without Anaplastic Lymphoma Kinase Gene Rearrangement in the Rectum with Liver Metastasis.
    Internal medicine (Tokyo, Japan), 2020, Feb-15, Volume: 59, Issue:4

    Topics: Aged, 80 and over; Anti-Inflammatory Agents; Fatal Outcome; Humans; Liver Neoplasms; Lymphoma; Male;

2020
An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy.
    Internal medicine (Tokyo, Japan), 2020, Feb-01, Volume: 59, Issue:3

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Middle Aged; Neopla

2020
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
    Urology, 2017, Volume: 109

    Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Diseas

2017
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
    BJU international, 2018, Volume: 121, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemot

2018
Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients.
    Urologic oncology, 2018, Volume: 36, Issue:2

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemothe

2018
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2018, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Afatinib; Aftercare; Antineoplastic Agents; Biopsy; Female; Humans; Lung Neoplasms;

2018
Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
    Clinical and experimental dermatology, 2018, Volume: 43, Issue:4

    Topics: Aged; Antineoplastic Agents, Immunological; Betamethasone; Glucocorticoids; Humans; Ipilimumab; Male

2018
Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
    Urologia internationalis, 2013, Volume: 91, Issue:4

    Topics: Aged; Betamethasone; Carcinoma, Renal Cell; Fatal Outcome; Humans; Kidney Neoplasms; Male; Neoplasm

2013
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:6

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T

2014
Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocol

2014
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.
    Chemotherapy, 2016, Volume: 61, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Evidence-Based Med

2016
Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
    BJU international, 2016, Volume: 118, Issue:6

    Topics: Aged; Antineoplastic Agents; Dexamethasone; Docetaxel; Drug Therapy, Combination; Glucocorticoids; H

2016
Idiopathic fibrosing mediastinitis mimicking nodal metastasis from breast cancer.
    Asian cardiovascular & thoracic annals, 2017, Volume: 25, Issue:9

    Topics: Biopsy; Breast Neoplasms; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Glucocorticoids;

2017
Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.
    Immunotherapy, 2017, Volume: 9, Issue:4

    Topics: Anemia; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cytokines; Drug-Related Side Ef

2017
Neurological picture. Vertebral sarcoidosis mimicking metastases.
    Journal of neurology, neurosurgery, and psychiatry, 2011, Volume: 82, Issue:2

    Topics: Anti-Inflammatory Agents; Biopsy; Diagnosis, Differential; Female; Humans; Immunosuppressive Agents;

2011
[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11

    Topics: Benzamides; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Imat

2010
Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report.
    World journal of gastroenterology, 2012, Dec-28, Volume: 18, Issue:48

    Topics: Carcinoma, Hepatocellular; Endoscopy; Gastritis; Gastrointestinal Hemorrhage; Hemostasis; Humans; Li

2012
Echocardiographic recognition of cardiac leukemic tumors in a child successfully treated with chemotherapy.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2003, Volume: 3, Issue:3

    Topics: Antineoplastic Agents; Asparaginase; Child; Diagnosis, Differential; Echocardiography; Heart Neoplas

2003
Nitrogen mustard in the palliation of lung and metastatic lung cancer.
    British journal of diseases of the chest, 1962, Volume: 56

    Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Mechlorethamine; Neopla

1962
[ENZYME DETERMINATIONS IN THE SERUM IN LIVER DISEASES. FUNCTION PATTERNS AS A MEANS OF DIAGNOSIS].
    Enzymologia biologica et clinica, 1963, Volume: 79

    Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Cholecystitis; C

1963
[SURGERY ON THE PITUITARY GLAND AND ANESTHESIA].
    [Chiryo] [Therapy], 1963, Volume: 45

    Topics: Adrenocorticotropic Hormone; Anesthesia; Breast Neoplasms; Cortisone; Desoxycorticosterone; Gonadotr

1963
CHLORAMBUCIL-PREDNISOLONE THERAPY FOR DISSEMINATED BREAST CARCINOMA.
    JAMA, 1964, Jul-06, Volume: 189

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Biomedical Research; Breast Neopl

1964
DEVELOPMENT OF SQUAMOUS CELL CARCINOMA IN BENIGN MUCOUS MEMBRANE PEMPHIGUS: REPORT OF A CASE.
    Australian journal of dermatology, 1964, Volume: 7

    Topics: Brain Neoplasms; Carcinoma, Squamous Cell; Humans; Mouth Diseases; Mouth Mucosa; Neoplasm Metastasis

1964
USE OF GLUCOCORTICOIDS IN THE PALLIATIVE TREATMENT OF METASTATIC BRAIN TUMORS.
    Cancer, 1965, Volume: 18

    Topics: Brain Neoplasms; Dexamethasone; Drug Therapy; Geriatrics; Glucocorticoids; Humans; Hydrocortisone; M

1965
HYPERCALCEMIA OF BREAST CANCER; MANAGEMENT WITH CORTICOSTEROIDS.
    Cancer, 1965, Volume: 18

    Topics: Adrenal Cortex Hormones; Breast Neoplasms; Calcium; Carcinoma; Drug Therapy; Geriatrics; Humans; Hyp

1965
Hypersensitivity pneumonitis associated with the use of trofosfamide.
    Anti-cancer drugs, 2004, Volume: 15, Issue:6

    Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro

2004
Concomitant deposition of aluminum and iron in bone marrow trabeculae.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:2

    Topics: Aluminum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin

2006
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
    Anti-cancer drugs, 2007, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochlori

2007
Technic and diagnostic value of the transparietohepatic cholangiography.
    The American journal of gastroenterology, 1967, Volume: 47, Issue:5

    Topics: Analgesics; Bile Duct Neoplasms; Cholangiography; Cholelithiasis; Cysts; Dexamethasone; Gallbladder

1967
[Diagnosis and therapy of micromolecular plasmocytomas -- a case report].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1980, Apr-01, Volume: 35, Issue:7

    Topics: Bence Jones Protein; Humans; Immunoglobulin kappa-Chains; Lumbar Vertebrae; Male; Melphalan; Middle

1980
VAP-cyclo: a short intensive regimen of chemotherapy for advanced breast cancer.
    Cancer treatment reports, 1982, Volume: 66, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

1982
Cyclophosphamide-prednisolone therapy in advanced prostatic carcinoma.
    Scandinavian journal of urology and nephrology. Supplementum, 1980, Volume: 55

    Topics: Acid Phosphatase; Cyclophosphamide; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Pr

1980
[Use of "split" courses of combination chemotherapy in breast cancer].
    Voprosy onkologii, 1981, Volume: 27, Issue:7

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil

1981
Corticosteroids for elderly patients with breast cancer.
    Cancer, 1981, Aug-15, Volume: 48, Issue:4

    Topics: Aged; Androgens; Breast Neoplasms; Cortisone; Estrogens; Female; Humans; Neoplasm Metastasis; Predni

1981
[Chemotherapy of breast cancer].
    Gynakologische Rundschau, 1981, Volume: 21 Suppl 2

    Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; N

1981
Multi-agent chemotherapy for mast cell tumours in the dog.
    The veterinary quarterly, 1998, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor

1998
Chemotherapy in the treatment of osteogenic sarcoma of the maxilla (case report).
    Journal of maxillofacial surgery, 1978, Volume: 6, Issue:4

    Topics: Alkaline Phosphatase; Bleomycin; Cyclophosphamide; Doxorubicin; Female; Humans; Maxillary Neoplasms;

1978
Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP).
    Cancer chemotherapy and pharmacology, 1979, Volume: 2, Issue:3

    Topics: Adolescent; Adult; Alopecia; Antineoplastic Agents; Bleomycin; Child; Doxorubicin; Drug Administrati

1979
Combination chemotherapy with 5--fluorouracil, amethopterin (methotrexate) and prednisolone (FAP protocol) in the therapy of cholangiocarcinoma.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1976, Volume: 59, Issue:8

    Topics: Adenoma, Bile Duct; Drug Therapy, Combination; Fluorouracil; Humans; Liver Neoplasms; Male; Methotre

1976
Early central nervous system involvement in adults with acute non-myelogenous leukaemia.
    British journal of cancer, 1977, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Asparaginase; Central Nervous System Diseases; Humans; Leukemia, Lymphoid; Middle

1977
Rapid platelet consumption in a case of metastatic osteogenic sarcoma of the breast.
    Acta pathologica et microbiologica Scandinavica. Section A, Pathology, 1978, Volume: 86A, Issue:6

    Topics: Aged; Blood Platelets; Blood Transfusion; Breast Neoplasms; Cell Survival; Female; Heart Neoplasms;

1978
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
    The Journal of urology, 1979, Volume: 121, Issue:6

    Topics: Chlorambucil; Drug Therapy, Combination; Estramustine; Humans; Male; Nausea; Neoplasm Metastasis; Ni

1979
Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone.
    Cancer, 1978, Volume: 41, Issue:2

    Topics: Aged; Bone Marrow; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle

1978
If I had Hodgkin's disease.
    British medical journal, 1978, May-20, Volume: 1, Issue:6123

    Topics: Drug Therapy, Combination; Hodgkin Disease; Humans; Neoplasm Metastasis; Neoplasm Staging; Nitrogen

1978
Combination chemotherapy with cyclophosphamide (NSC-26 271), methotrexate (NSC-740), and prednisolone (NSC-9 900) (CMP protocol), for metastatic breast cancer.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1978, Volume: 61, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Methotre

1978
Combination therapy in metastatic breast cancer.
    Annals of internal medicine, 1977, Volume: 86, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Humans; Middle Aged;

1977
Combination chemotherapy for thrombocytopenia with bone marrow metastases from breast cancer.
    British medical journal, 1977, Feb-26, Volume: 1, Issue:6060

    Topics: Adult; Bone Marrow Diseases; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Human

1977
[Combined leukeran-prednisolone therapy in metastasizing breast cancer].
    Fortschritte der Medizin, 1977, Apr-21, Volume: 95, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Huma

1977
Acute cardiac pain and electrocardiographic changes following cytotoxic treatment for metastatic carcinoma.
    Clinical oncology, 1976, Volume: 2, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Coronary Disease; Cyclophosphamide;

1976
Hydroxyproline excretion in patients with breast cancer and response to treatment.
    British medical journal, 1975, Apr-26, Volume: 2, Issue:5964

    Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Ethinyl Estradiol; Female; Humans;

1975
[Evaluation of the immunological reactivity of melanoma patients using the rosette formation test].
    Doklady Akademii nauk SSSR, 1975, May-11, Volume: 222, Issue:2

    Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immune Adherence Reaction; Immunosuppre

1975
Leucoerythroblastic anaemia in carcinoma of ovary.
    Strahlentherapie, 1975, Volume: 150, Issue:1

    Topics: Anemia, Myelophthisic; Bone Marrow Examination; Cystadenocarcinoma; Female; Humans; Middle Aged; Neo

1975
[Blood coagulation system in oncological patients treated with rubomycin, adriamycin and carminomycin].
    Antibiotiki, 1976, Volume: 21, Issue:3

    Topics: Antibiotics, Antineoplastic; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Carubicin;

1976
On long-term survivals in non-Hodgkin's lymphoma with 'gentle' treatment.
    Clinical radiology, 1976, Volume: 27, Issue:2

    Topics: Adult; Aged; Child; Chlorambucil; Female; Follow-Up Studies; Humans; Lymph Nodes; Lymphoma; Male; Mi

1976
Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.
    Cancer, 1992, Feb-01, Volume: 69, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclo

1992
Cancer in mice: effects of prednisolone or mepacrine alone and with cytotoxic drugs.
    British journal of cancer, 1987, Volume: 55, Issue:4

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Female; Male; Mammary Neoplasms, Experimental; Melphalan; Met

1987
Deoxyribonucleic acid (DNA) content of primary carcinoma and response to endocrine or cytotoxic drug therapies in patients with advanced breast cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1985, Volume: 11, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Combined Modality Ther

1985
Common medical problems in disseminated cancer.
    Geriatrics, 1970, Volume: 25, Issue:10

    Topics: Androgens; Brain Neoplasms; Chlorothiazide; Dactinomycin; Estrogens; Humans; Hypercalcemia; Lymphede

1970
Paraplegia in childhood malignant disease.
    Acta paediatrica Scandinavica, 1967

    Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Female; Humans; Infant; Leukemi

1967
Chemotherapy of breast cancer by regional intra-arterial infusion.
    Cancer, 1970, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Brachial Artery; Breast Neoplasms; Carotid Arteries; Cyclophosph

1970
Metastatic adrenal cortical carcinoma: biochemical changes accompanying clinical regression during therapy with o,p'-DDD.
    Clinical chemistry, 1971, Volume: 17, Issue:12

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Abdominal Neoplasms; Acetates; Adrenal Gland Neoplasms;

1971
[Adriamycin in the therapy of child leukemias and tumors].
    Monatsschrift fur Kinderheilkunde, 1973, Volume: 121, Issue:7

    Topics: Acute Disease; Adolescent; Doxorubicin; Humans; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neo

1973
[Late results of breast cancer treatment].
    Voprosy onkologii, 1973, Volume: 19, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Breast Neoplasms; Carcinoma; Carcinoma, Intraducta

1973
[Complex treatment with radiation action on the hypophysis in generalized breast cancer].
    Meditsinskaia radiologiia, 1974, Volume: 19, Issue:7

    Topics: Breast Neoplasms; Female; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Pituitary Irradiatio

1974
Intracerebral Burkitt's lymphoma: pathology, clinical features and treatment.
    The Quarterly journal of medicine, 1974, Volume: 43, Issue:172

    Topics: Adolescent; Allopurinol; Brain Neoplasms; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamid

1974
[Indications for radiotherapy of acute leukemia in children with special reference to clinically non-manifest involvement of CNS].
    Strahlentherapie, 1974, Volume: 147, Issue:2

    Topics: Age Factors; Brain Neoplasms; Child; Cobalt Radioisotopes; Cyclophosphamide; Germany, West; Humans;

1974
Blood and neoplastic diseases. Acute lymphoblastic leukaemia.
    British medical journal, 1974, Nov-02, Volume: 4, Issue:5939

    Topics: Arachnoid; Asparaginase; Brain Neoplasms; Cerebrospinal Fluid; Child; Cyclophosphamide; Daunorubicin

1974
A case of bullous pemphigoid and figurate erythema in association with metastatic spread of carcinoma.
    The British journal of dermatology, 1973, Volume: 88, Issue:4

    Topics: Adenocarcinoma; Alkaline Phosphatase; Eosinophils; Erythema; Fluorescent Antibody Technique; Hepatom

1973
Renal transplantation in patients with carcinoma.
    British medical journal, 1974, Oct-19, Volume: 4, Issue:5937

    Topics: Adult; Angiography; Azathioprine; Cadaver; Female; Graft Rejection; Hematuria; Humans; Immunosuppres

1974
Blood and neoplastic diseases. Treatment of the lymphomas.
    British medical journal, 1974, Dec-28, Volume: 4, Issue:5947

    Topics: Alopecia; Bone Marrow; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Ne

1974
[Hormonal prevention of recurrence and metastasis in the complex treatment of breast cancer].
    Voprosy onkologii, 1968, Volume: 14, Issue:3

    Topics: Adult; Aged; Androgens; Breast Neoplasms; Castration; Estrogens; Female; Humans; Mastectomy; Middle

1968
[Hemangiopericytoma with metastases. Effect of prednisone treatment].
    Pediatrie, 1971, Volume: 26, Issue:8

    Topics: Brain Diseases; Buttocks; Child, Preschool; Cysts; Hemangiopericytoma; Humans; Infant; Infant, Newbo

1971
Comparison of CNS-leukaemia in children with acute leukaemia, induced either with rubidomycin or L-asparaginase.
    Padiatrie und Padologie, 1971, Volume: 6, Issue:3

    Topics: Asparaginase; Central Nervous System Diseases; Child; Child, Preschool; Daunorubicin; Drug Therapy,

1971
[Metastic tumors of the brain].
    No to shinkei = Brain and nerve, 1967, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Breast Neoplasms; Cerebral Angiography; Cerebral Ventricul

1967
Cerebral metastases from carcinoma of the lung.
    The Medical journal of Australia, 1969, Jul-26, Volume: 2, Issue:4

    Topics: Aged; Betamethasone; Brain; Brain Neoplasms; Carcinoma; Carotid Arteries; Cerebral Ventriculography;

1969
[Clinical aspects of malignant pleurisy].
    Radiologia diagnostica, 1970, Volume: 11, Issue:5

    Topics: Adult; Aged; Biopsy; Diagnosis, Differential; Female; Humans; Male; Mesothelioma; Middle Aged; Neopl

1970
Pure red cell aplasia and carcinoma.
    Blood, 1971, Volume: 37, Issue:5

    Topics: Adenocarcinoma; Aged; Anemia, Aplastic; Autopsy; Blood Transfusion; Bone Marrow Examination; Chromiu

1971
Bilateral inflammatory pseudotumors of the ciliary body.
    American journal of ophthalmology, 1971, Volume: 72, Issue:3

    Topics: Administration, Topical; Anti-Inflammatory Agents; Atropine; Biopsy; Ciliary Body; Diagnosis, Differ

1971
[Leucosarcomatosis with heart metastasis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1967, Mar-15, Volume: 22, Issue:6

    Topics: Adult; Anti-Bacterial Agents; Blood Transfusion; Bone Marrow Examination; Heart Neoplasms; Humans; L

1967
Methotrexate for advanced cancer of the breast.
    Cancer, 1968, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Androgens; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Met

1968
[Hypercalcemic crisis and hypocalcemic tetany during treatment with sex hormones in a case of breast carcinoma with metastasis in the skeleton and parathyroid glands].
    Wiener klinische Wochenschrift, 1966, Oct-14, Volume: 78, Issue:41

    Topics: Blood Chemical Analysis; Blood Sedimentation; Bone Marrow Examination; Bone Neoplasms; Breast Neopla

1966
[Cytostatic therapy of choroid membrane metastases].
    Klinische Monatsblatter fur Augenheilkunde, 1966, Volume: 148, Issue:6

    Topics: Aged; Breast Neoplasms; Chlorambucil; Choroid Neoplasms; Cyclophosphamide; Female; Humans; Mastectom

1966
chemdatabank.com